These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30934169)

  • 1. Population Pharmacokinetics and Pharmacodynamics of Teicoplanin and C-Reactive Protein in Hospitalized Patients With Gram-Positive Infections.
    Ogami C; Tsuji Y; Muraki Y; Mizoguchi A; Okuda M; To H
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):175-188. PubMed ID: 30934169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Ryder SA; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; D'Arcy DM; McHugh J
    Clin Microbiol Infect; 2017 Sep; 23(9):674.e7-674.e13. PubMed ID: 28267636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection.
    Ogawa R; Kobayashi S; Sasaki Y; Makimura M; Echizen H
    Int J Clin Pharmacol Ther; 2013 May; 51(5):357-66. PubMed ID: 23458228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.
    Ramos-Martín V; Neely MN; McGowan P; Siner S; Padmore K; Peak M; Beresford MW; Turner MA; Paulus S; Hope WW
    J Antimicrob Chemother; 2016 Nov; 71(11):3168-3178. PubMed ID: 27543654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
    J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections.
    Cojutti PG; Tedeschi S; Zamparini E; Viale P; Pea F
    Clin Pharmacokinet; 2024 Sep; 63(9):1271-1282. PubMed ID: 39172334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.
    Yamada T; Nonaka T; Yano T; Kubota T; Egashira N; Kawashiri T; Oishi R
    Int J Antimicrob Agents; 2012 Oct; 40(4):344-8. PubMed ID: 22818770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?
    Kontou A; Sarafidis K; Begou O; Gika HG; Tsiligiannis A; Ogungbenro K; Dokoumetzidis A; Agakidou E; Roilides E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme.
    Lamont E; Seaton RA; Macpherson M; Semple L; Bell E; Thomson AH
    J Antimicrob Chemother; 2009 Jul; 64(1):181-7. PubMed ID: 19411678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.
    Matsumoto K; Kanazawa N; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2010 Jun; 16(3):193-9. PubMed ID: 20195882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teicoplanin pharmacokinetics in pediatric patients.
    Dufort G; Ventura C; Olivé T; Ortega JJ
    Pediatr Infect Dis J; 1996 Jun; 15(6):494-8. PubMed ID: 8783345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose.
    Pea F; Brollo L; Viale P; Pavan F; Furlanut M
    J Antimicrob Chemother; 2003 Apr; 51(4):971-5. PubMed ID: 12654757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.
    Zhao W; Zhang D; Storme T; Baruchel A; Declèves X; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2015 Nov; 80(5):1197-207. PubMed ID: 26138279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal Teicoplanin Dosing Regimen in Neonates and Children Developed by Leveraging Real-World Clinical Information.
    Yamada T; Emoto C; Fukuda T; Motomura Y; Inoue H; Ohga S; Ieiri I
    Ther Drug Monit; 2022 Jun; 44(3):404-413. PubMed ID: 34629445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.
    Barbot A; Venisse N; Rayeh F; Bouquet S; Debaene B; Mimoz O
    Intensive Care Med; 2003 Sep; 29(9):1528-34. PubMed ID: 12856119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of teicoplanin in children.
    Ramos-Martín V; Paulus S; Siner S; Scott E; Padmore K; Newland P; Drew RJ; Felton TW; Docobo-Pérez F; Pizer B; Pea F; Peak M; Turner MA; Beresford MW; Hope WW
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6920-7. PubMed ID: 25224001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
    Wang T; Li N; Hu S; Xie J; Lei J; Wang Y; Zheng X; Xing J; Dong Y
    Int J Clin Pharmacol Ther; 2015 May; 53(5):356-62. PubMed ID: 25828639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition.
    Emoto C; Johnson TN; Yamada T; Yamazaki H; Fukuda T
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1157-1168. PubMed ID: 33527208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of teicoplanin in patients undergoing chronic haemodialysis.
    Papaioannou MG; Marinaki S; Pappas M; Stamatiadis D; Giamarellos-Bourboulis EJ; Giamarellou H; Stathakis C
    Int J Antimicrob Agents; 2002 Mar; 19(3):233-6. PubMed ID: 11932147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.